Canopy Growth Corporation — FY2020 Form 10-K Summary
Period: Fiscal year ended March 31, 2020; filed June 1, 2020. The request metadata says “2019 Q4,” but this filing reports FY2020, including the quarter ended March 31, 2020. Figures are in Canadian dollars unless stated otherwise.
Business context
Canopy Growth produces, distributes and sells cannabis, hemp-derived and other consumer products for recreational and medical use. Its reportable segments are Cannabis, Hemp and Other Consumer Products and Canopy Rivers; Canopy Rivers generated no revenue in the three years ended March 31, 2020. Shares trade as CGC on the NYSE and WEED on the TSX.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Net revenue | $398.8 million | $226.3 million |
| Gross margin | $(31.7) million; (8%) | $28.2 million; 12% |
| Net loss | $(1.387) billion | $(712.0) million |
| Net loss attributable to Canopy Growth | $(1.321) billion | $(736.3) million |
| Adjusted EBITDA loss (non-GAAP) | $(442.8) million | $(288.9) million |
| Cash used in operating activities | $772.6 million | $535.0 million |
| Free cash flow (non-GAAP) | $(1.478) billion | $(1.179) billion |
Revenue increased 76%, reflecting a full year of Canadian recreational sales, international medical growth and acquired businesses. Recreational revenue was $209.3 million; medical revenue was $124.8 million, including $68.0 million internationally; and other revenue was $105.5 million. Cannabis sold totaled 46,323 kilograms and equivalents, up 90% year over year. Average recreational selling price fell 22% to $5.65 per gram, while total medical average selling price rose 58% to $14.76, partly reflecting the C3 acquisition.
Gross margin turned negative despite revenue growth. FY2020 cost of goods sold was $430.5 million. Inventory write-downs and related charges included $132.1 million recorded in cost of goods sold, including $76.2 million of inventory write-downs and $55.9 million of restructuring-related charges.
At March 31, 2020, cash and cash equivalents were $1.303 billion and short-term investments were $673.3 million. Total assets were $6.858 billion and total liabilities were $1.680 billion. Debt had a reported carrying amount of $465.4 million; principal outstanding was $615.2 million, including $600 million of 4.25% convertible notes due July 2023. The difference principally reflects fair-value accounting for the notes. The company also had a $40 million revolving facility, with $5.3 million outstanding. Total contractual obligations and commitments were $1.619 billion.
Material changes and unusual items
- FY2020 included $843.3 million of restructuring, asset impairment and related charges, including $335.0 million for property and equipment impairment or abandonment and $247.0 million for intangible-asset impairment or abandonment. The company also recorded $55.2 million of impairment losses on equity-method investments.
- The strategic review led to greenhouse closures, exits from South Africa and Lesotho and New York hemp farming, a changed Colombia strategy, reduced marketing and R&D activity, and approximately 600 job eliminations.
- Other income, net, was $224.3 million, but included significant non-cash fair-value movements: notably a $795.1 million gain on the CBI warrant derivative liability, partly offset by a $645.2 million loss on the Acreage arrangement liability and losses on other financial assets. These valuation movements contributed to volatile quarterly results; FY2020’s second-quarter net income included substantial fair-value effects.
- Cash and cash equivalents declined from $2.481 billion to $1.303 billion; cash plus short-term investments declined from approximately $4.515 billion to $1.977 billion. Capital spending on property, plant and equipment was $704.9 million.
- On May 1, 2020, after year-end, a CBI subsidiary exercised warrants for approximately $245 million in proceeds. CBI’s ownership then stood at 38.6%; full exercise of remaining warrants and conversion of its notes could raise it to approximately 55.8%, before any Acreage-related effects.
Outlook, commentary and risks
Management described FY2021 as a transition year, with a reset strategic focus, new organizational design and operational improvement program. The company gave no clear quantified revenue, earnings or cash-flow guidance in the provided filing text. Management said it expected COVID-19 to negatively affect first-quarter FY2021 results and could not estimate the pandemic’s longer-term financial impact. It stated that year-end liquidity, together with the subsequent $245 million CBI warrant exercise, was sufficient to fund operations and planned commitments.
Key risks include continued operating losses and cash burn; oversupply, falling prices and inventory obsolescence; uncertain consumer demand and execution of new products; COVID-19 disruption; evolving cannabis and hemp regulation, especially U.S. federal restrictions and FDA uncertainty around CBD; reliance on provincial purchasers without minimum purchase commitments; and the conditional, potentially dilutive Acreage transaction. CBI’s significant ownership, governance and consent rights may influence corporate decisions. The company also disclosed a pending, uncertified securities class action alleging misleading statements concerning receivables, demand and business prospects; two of three initial complaints had been dismissed, and the company intended to defend the action.
Management reported effective disclosure controls and internal control over financial reporting at March 31, 2020, and said a previously identified spreadsheet-control material weakness had been remediated. The auditor issued unqualified opinions on the financial statements and internal controls, while excluding certain recent acquisitions from its internal-control audit scope.
Most important facts for investors to verify
- Whether revenue growth can translate into positive gross margins and lower operating cash outflows after the large inventory and asset write-downs.
- How much of the $1.977 billion in cash and short-term investments remains available after continuing cash burn, capital spending and contractual commitments.
- The assumptions and sensitivity behind Level 3 fair values for the Acreage liability, CBI warrant liability and other investments, which materially affected reported earnings.
- Inventory quality, expected sell-through, returns and price adjustments, particularly following the $132.1 million of FY2020 inventory-related charges.
- Progress on operational restructuring, cost reductions and the company’s path to profitability, alongside the effects of COVID-19.
- The status, conditions, potential share issuance and CBI-related governance implications of the Acreage arrangement and remaining warrants and convertible notes.